Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONCY Oncolytics Biotech Inc

Post-Mkt 04-02 19:51:37 EDT

0.9603

+0.0302

+3.25%

盘后0.9600

-0.0003-0.03%

19:16 EDT

High0.9812	Low0.9131	Vol640.38K
Open0.9199	D1 Closing0.9301	Amplitude7.32%
Mkt Cap111.52M	Tradable Cap109.47M	Total Shares116.13M
T/O616.19K	T/O Rate0.56%	Tradable Shares114.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":0.9603,"timestamp":1775160000000,"preClose":0.9301,"halted":0,"volume":640378,"hourTrading":{"tag":"盘后","latestPrice":0.96,"preClose":0.9603,"latestTime":"19:16 EDT","volume":2225,"amount":2138.7131649999997,"timestamp":1775171774709,"change":-0.0003,"changeRate":-0.000312,"amplitude":0.021868},"delay":0,"changeRate":0.032469626921836366,"floatShares":113999999,"shares":116128162,"eps":-0.300019,"marketStatus":"Post-Mkt","change":0.0302,"latestTime":"04-02 19:51:37 EDT","open":0.9199,"high":0.9812,"low":0.9131,"amount":616191.78104652,"amplitude":0.073218,"askPrice":0.9866,"askSize":50,"bidPrice":0.9131,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.300019,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1775174400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":0.9301,"preHourTrading":{"tag":"盘前","latestPrice":0.93,"preClose":0.9301,"latestTime":"09:21 EDT","volume":16969,"amount":15898.0507751,"timestamp":1775136096445,"change":-0.0001,"changeRate":-0.000108,"amplitude":0.064509},"postHourTrading":{"tag":"盘后","latestPrice":0.96,"preClose":0.9603,"latestTime":"19:16 EDT","volume":2225,"amount":2138.7131649999997,"timestamp":1775171774709,"change":-0.0003,"changeRate":-0.000312,"amplitude":0.021868},"volumeRatio":0.689816},"requestUrl":"/m/hq/s/ONCY","defaultTab":"news","newsList":[{"id":"2624682125","title":"Top News Today/Canada: Goods-Trade Deficit Widens, Surplus With U.S. Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2624682125","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624682125?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:29","pubTimestamp":1775161740,"startTime":"0","endTime":"0","summary":"Goods-Trade Deficit Widens to Six-Month High Even as Trade With Non-U.S. Nations Increases. Canada's trade deficit with the world surged to a six-month high as shipments of gold drove imports to record levels, though evidence is growing the country's dependence on the massive U.S. market is easing.The country recorded a merchandise-trade deficit in February of C$5.74 billion, Statistics Canada said Thursday. That was much larger than the C$2.5 billion shortfall economists anticipated.Imports jumped 8.4% between January and February to an all-time high of C$72.05 billion as inbound shipments of gold led widespread increases, outpacing a 6.4% rise in exports to C$66.31 billion, the highest since March of last year when the first wave of the Trump administration's tariffs kicked in.Telecom Stocks Drop as TD Cowen Downgrades Sector on Price War Pressures. Canadian telecom stocks slipped after TD Cowen cut its outlook on the sector amid mounting pressure from aggressive mobile-plan pricing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","RBCN","BK4104","BPTH","BK4096","BK4007","CARM","SCLX","AAME","BK4524","BK4600","NWBO","ATLN","BK4507","BK4170","RHEP","BK4147","BK4209","SMXT","MPU","BK4185","BK4108","BK4139","BK4117","SONM","BK4121","ONCY","NROM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624344511","title":"Oncolytics completes domicile change to the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2624344511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624344511?lang=en_us&edition=fundamental","pubTime":"2026-04-01 21:39","pubTimestamp":1775050777,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) announced the completion of the previously announced change in the jurisdiction of incorporation of Oncolytics from the Province ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-completes-domicile-change-to-the-u-s-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-completes-domicile-change-to-the-u-s-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624951644","title":"Oncolytics Biotech shifts headquarters to San Diego, completes Nevada domestication","url":"https://stock-news.laohu8.com/highlight/detail?id=2624951644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624951644?lang=en_us&edition=fundamental","pubTime":"2026-04-01 21:02","pubTimestamp":1775048541,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech completed a corporate domicile change to United States, shifting incorporation from Alberta to Nevada.San Diego office becomes new headquarters, while Calgary office is retained.Domestication took effect March 31, 2026 following filings with Nevada Secretary of State.Company cited operational efficiency, streamlined regulatory structure, improved access to U.S. capital markets.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL3nLpHg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","BK4112","SG9999014021.USD","SG9999014005.SGD","NDAQ","LU0314104364.USD","BK4588","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","LU2095319765.USD","IE00BN0W2W23.USD","BK4585","SG9999014013.SGD","ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624940995","title":"Oncolytics files $250M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2624940995","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624940995?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:11","pubTimestamp":1775038298,"startTime":"0","endTime":"0","summary":"06:07 EDT Oncolytics (ONCY) files $250M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-files-250m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-files-250m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624594511","title":"Oncolytics Biotech Inc - May Offer up to $250 Mln in Aggregate Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624594511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624594511?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:06","pubTimestamp":1775038013,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40J204:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623732843","title":"Oncolytics Biotech Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2623732843","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623732843?lang=en_us&edition=fundamental","pubTime":"2026-03-31 09:01","pubTimestamp":1774918918,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc reports results for the quarter ended December 31 - Earnings SummaryOncolytics Biotech Inc ONCY.OQ reported a quarterly adjusted loss of 8 cents per share for the quarter ended ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL8N40J017:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623532455","title":"Oncolytics FY25 net loss widens to $ US 29M; operating loss grows to $ US 29M","url":"https://stock-news.laohu8.com/highlight/detail?id=2623532455","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623532455?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:32","pubTimestamp":1774906358,"startTime":"0","endTime":"0","summary":"Oncolytics posted net loss of USD 29 million, widening from USD 23 million.Operating loss expanded to USD 29 million from USD 26 million as operating expenses climbed to USD 29 million from USD 26 million.Research and development expense fell to USD 13 million from USD 15 million, while general and administrative costs rose to USD 15 million from USD 10 million on higher public company-related expenses tied to domestication activities and TSX delisting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 30, 2026, an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL8bG9sw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622273852","title":"Geron appoints Patricia S. Andrews and Constantine Chinoporos to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2622273852","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622273852?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:04","pubTimestamp":1774526679,"startTime":"0","endTime":"0","summary":"Patricia Andrews is a board member at Glenmark Pharmaceuticals and Oncolytics Biotech, and previously served as CEO of Sumitomo Pharma Oncology from 2017 to 2023.Constantine Chinoporos previously served as COO and chief business officer at Applied Therapeutics from 2023 until its acquisition by Cycle Pharmaceuticals in 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL913xVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","ONCY","BK4588","SG9999014039.USD","IE00B64PRP62.GBP","BK4139","BK4585","GERN","SG9999014021.USD","IE00BN0W2W23.USD","LU2210149790.SGD","NDAQ","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620273897","title":"Oncolytics Biotech Showcases Pelareorep as Immune-Priming Backbone With New AACR 2026 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2620273897","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620273897?lang=en_us&edition=fundamental","pubTime":"2026-03-20 02:05","pubTimestamp":1773943540,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech ( ($ONCY) ) just unveiled an announcement. Oncolytics Biotech will present new mechanistic and translational data at the AACR 20...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oncolytics-biotech-showcases-pelareorep-as-immune-priming-backbone-with-new-aacr-2026-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oncolytics-biotech-showcases-pelareorep-as-immune-priming-backbone-with-new-aacr-2026-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4595","BK4588","BK4585","ONCY","BK4600","BTFL","BK4581","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620255702","title":"Oncolytics to present new data on Pelareorep at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620255702","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620255702?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:16","pubTimestamp":1773926207,"startTime":"0","endTime":"0","summary":"The company states: “Oncolytics (ONCY) Biotech announced two abstracts across distinct tumor types were accepted for presentation at the American A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-to-present-new-data-on-pelareorep-at-aacr-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-to-present-new-data-on-pelareorep-at-aacr-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4581","ONCY","BK4585","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620223128","title":"Oncolytics Biotech to present pelareorep data at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620223128","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620223128?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:02","pubTimestamp":1773925336,"startTime":"0","endTime":"0","summary":"Oncolytics will present two abstracts at the American Association for Cancer Research  Annual Meeting 2026, held April 17-22, 2026.The meeting is scheduled at the San Diego Convention Center in San Diego, California.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL8KhKBj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014021.USD","IE00BKPKM429.USD","BK4585","IE00B64PRP62.GBP","BK4588","IE00BN0W2W23.USD","NDAQ","LU0314104364.USD","SG9999014013.SGD","ONCY","SG9999014039.USD","BK4139","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","BK4112","LU2095319765.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620257052","title":"Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620257052","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620257052?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:00","pubTimestamp":1773925200,"startTime":"0","endTime":"0","summary":"Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational data suggest potential to boost response to immunotherapy and targeted therapy in RAS-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259093/0/en/Oncolytics-Biotech-to-Present-New-Mechanistic-and-Translational-Data-Supporting-Pelareorep-as-an-Immune-Priming-Backbone-at-AACR-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4595","BK4581","BK4588","BK4600","ONCY","BTFL","BK4023","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619949031","title":"Oncolytics Biotech CEO Jared Kelly Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2619949031","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619949031?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:00","pubTimestamp":1773403243,"startTime":"0","endTime":"0","summary":"Jared Kelly, Chief Executive Officer and director of Oncolytics Biotech Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDLXTHdz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Oncolytics Biotech CEO Jared Kelly Reports Acquisition of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616810326","title":"Oncolytics Biotech Inc  expected to post a loss of 9 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2616810326","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616810326?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:15","pubTimestamp":1772547308,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc  expected to post a loss of9cents a share - Earnings Preview Oncolytics Biotech Inc ONCY.OQ ONCY.O is expected to  show no change in quarterly revenue when it reports  results o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL8N3ZR1UQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616358796","title":"Oncolytics Biotech Inc - Initiates Phase 2 Study for Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616358796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616358796?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:17","pubTimestamp":1772461037,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ0X0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616651358","title":"Oncolytics Biotech launches REO 033 Phase 2 metastatic colorectal cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2616651358","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616651358?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:01","pubTimestamp":1772460081,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc. has initiated a Phase 2 randomized study  in second-line RAS-mutated, microsatellite-stable metastatic colorectal cancer. The trial will compare a control regimen of bevacizumab plus FOLFIRI versus an experimental regimen of pelareorep plus bevacizumab and FOLFIRI, with objective response rate as the primary endpoint and progression-free survival, overall survival, safety, and biomarker analyses as additional endpoints. The company said preliminary results are expected by the end of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDLdxDyT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","SG9999014021.USD","LU2095319765.USD","LU0314104364.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","ONCY","BK4139","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","NDAQ","BK4112","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614316700","title":"Lake Street Sticks to Their Buy Rating for Oncolytics Biotech (ONCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614316700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614316700?lang=en_us&edition=fundamental","pubTime":"2026-02-26 00:05","pubTimestamp":1772035546,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer maintained a Buy rating on Oncolytics Biotech today and set a price target of $7.00. According to TipRanks, Messer ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-their-buy-rating-for-oncolytics-biotech-oncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-their-buy-rating-for-oncolytics-biotech-oncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614038755","title":"Oncolytics Biotech (ONCY) Valuation Check After Recent Share Price Momentum And Conflicting Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2614038755","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614038755?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:28","pubTimestamp":1772026124,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech (ONCY) has attracted fresh attention after a recent move in its share price, with the stock closing at US$1.13 and showing mixed return patterns across the past year and over multiple years.\nSee our latest analysis for Oncolytics Biotech.\nThe recent 6.6% 1 day share price return and 10.8% 7 day share price return suggest short term momentum is building around Oncolytics Biotech, even as the 58.3% 1 year total shareholder return contrasts with weaker 3 and 5 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oncy/oncolytics-biotech/news/oncolytics-biotech-oncy-valuation-check-after-recent-share-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oncy/oncolytics-biotech/news/oncolytics-biotech-oncy-valuation-check-after-recent-share-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4588","LABU","DCF","BK4585","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613178457","title":"Oncolytics Biotech to Prioritize Registration-Focused Studies in Anal and Colorectal Cancer, Wind Down GOBLET Enrollment and Seek FDA Alignment on SCAC Trial Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2613178457","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613178457?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:01","pubTimestamp":1771941677,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech to Prioritize Registration-Focused Studies in Anal and Colorectal Cancer, Wind Down GOBLET Enrollment and Seek FDA Alignment on SCAC Trial Design. Oncolytics Biotech Inc. plans to wind down its GOBLET gastrointestinal study and reallocate resources toward registration-focused and registration-enabling programs for pelareorep in squamous cell anal cancer  and metastatic colorectal cancer . The company expects to meet with the U.S. Food and Drug Administration in mid-April to align on the design of a U.S.-based single-arm SCAC registrational study, which it believes could enroll well under 100 patients. Oncolytics will stop further enrollment in the GOBLET Cohort 5 metastatic pancreatic ductal adenocarcinoma arms at about 20 patients per arm, continue following enrolled patients, and report results when the data mature.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL3Tj1fl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","NDAQ","BK4112","ONCY","SG9999014021.USD","LU0314104364.USD","BK4588","SG9999014039.USD","SG9999014005.SGD","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014013.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611159069","title":"Oncolytics Biotech Director Deborah Margaret Brown Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611159069","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611159069?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:01","pubTimestamp":1770984072,"startTime":"0","endTime":"0","summary":"Deborah Margaret Brown, Director at Oncolytics Biotech Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL7lZcpP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0209},{"period":"1month","weight":-0.0881},{"period":"3month","weight":0.0642},{"period":"6month","weight":-0.326},{"period":"1year","weight":0.7649},{"period":"ytd","weight":0.0642}],"compareEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":-0.0454},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0209},{"period":"1year","weight":0.168},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.001975},{"month":2,"riseRate":0.25,"avgChangeRate":-0.025046},{"month":3,"riseRate":0.125,"avgChangeRate":-0.123611},{"month":4,"riseRate":0.75,"avgChangeRate":0.031982},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.009291},{"month":6,"riseRate":0.285714,"avgChangeRate":0.190573},{"month":7,"riseRate":0.5,"avgChangeRate":0.009647},{"month":8,"riseRate":0.25,"avgChangeRate":-0.092405},{"month":9,"riseRate":0.125,"avgChangeRate":-0.025103},{"month":10,"riseRate":0.5,"avgChangeRate":0.144514},{"month":11,"riseRate":0.25,"avgChangeRate":0.020161},{"month":12,"riseRate":0.125,"avgChangeRate":0.270533}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}